1 Schwitzer G, Mudur G, Henry D et al. What are the
roles and responsibilities of the media in disseminating
health information? Public Library of Science
Medicine 2005; 2 (doi: 10.1371/journal.
pmed.0020215).
2 Entwistle V. Reporting research in medical journals
and newspapers. British Medical Journal, 1995; 310:
920–923.
3 Entwistle V, Hancock-Beaulieu M. Health and medical
coverage in the UK national press. Public
Understanding of Science, 1992; 1: 367–382.
4 Entwistle VA, Watt IS, Bradbury R et al. Media
coverage of the Child B case. British Medical Journal,
1996; 312: 1587–1591.
5 Chan AW, Altman DG. Identifying outcome reporting
bias in randomised trials on PubMed: review of
publications and survey of authors. British Medical
Journal, 2005; 330: 753.
6 Ioannidis JPA, Lau J. Completeness of safety
reporting in randomized trials: an evaluation of 7
medical areas. Journal of the American Medical
Association, 2001; 285: 437–443.
7 Mayor S. The public needs better understanding of
drug regulation. British Medical Journal, 2006; 332:
990–99a.
8 Jefford M, Savulescu J, Thomson J et al. Medical
paternalism and expensive unsubsidised drugs. British
Medical Journal, 2005; 331: 1075–1077.
9 Romond EH, Perez EA, Bryant J et al. Trastuzumab
plus adjuvant chemotherapy for operable HER2-positive
breast cancer. New England Journal of Medicine,
2005; 353: 1673–1684.
10 National Institute for Health and Clinical Excellence.
Trastuzumab for the adjuvant treatment of early stage
HER2-positive breast cancer, London: NICE, 2006.
11 Rosen PP, Groshen S, Saigo PE et al. A long-term
follow-up study of survival in stage I (T1N0M0) and
stage II (T1N1M0) breast carcinoma. Journal of
Clinical Oncology, 1989; 7: 355–366.
12 Bonadonna G, Valagussa P, Moliterni A et al.
Adjuvant cyclophosphamide, methotrexate, and fluorouracil
in node-positive breast cancer: the results of 20 years of follow-up. New England Journal of Medicine,
1995; 332: 901–906.
13 Hind D, Pilgrim H, Ward S. Questions about adjuvant
trastuzumab still remain. The Lancet, 2007; 369:
3–5.
14 Moynihan R, Bero L, Ross-Degnan D et al. Coverage
by the news media of the benefits and risks of
medications. New England Journal of Medicine, 2000;
342: 1645–1650.
15 Schwitzer G. The seven words you shouldn't use in
medical news. 2002. Available at: http://www.tc.um
n.edu/~schwitz/The7words.htm, accessed 4 February
2009.
16 Herceptin: summary of product characteristics. 2009.
Available at: http://www.medicines.org.uk, accessed 4
February 2009.
17 Newcombe RG. Two-sided confidence intervals for
the single proportion: comparison of seven methods.
Statistics in Medicine, 2008; 17: 857–872.
18 McNemar Q. Note on the sampling error of the difference
between correlated proportions or percentages.
Psychometrika, 1947; 12: 151–153.
19 King's Fund. Policy position: NICE and Herceptin
(November 2005). Available at: http://www.kings
fund.org.uk/news/briefings/policy_position.html,
accessed 4 February 2009.
20 Trastuzumab in combination therapy for HER2-positive
early breast cancer patients. San Antonio Breast
Cancer Symposium Newsletter 2: 2–3. 2005.
21 Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al.
Adjuvant docetaxel or vinorelbine with or without
trastuzumab for breast cancer. [see comment]. New
England Journal of Medicine, 2006; 354: 809–820.
22 Deacon D, Pickering M, Golding P, Murdock G
Unpacking news. In: Researching Communications: A
Practical Guide to Methods in Media and Cultural
Analysis. London: Arnold, 1999: 162–184.
23 Schlesinger P. Putting ‘‘Reality’’ Together. London:
Methuen, 1978.
24 Boseley S. The selling of a wonder drug. Guardian, 29
March 2006.
25 Wilson PM, Booth AM, Eastwood A et al. Deconstructing
media coverage of trastuzumab (Herceptin):
an analysis of national newspaper coverage. Journal
of the Royal Society of Medicine, 2008; 101: 125–132.
26 Harrabin R, Coote A, Allen J. Health in the News:
Risk, Reporting and Media Influence. London: King's
Fund, 2003.
27 Schwitzer G. How do US journalists cover treatments,
tests, products, and procedures? An evaluation
of 500 stories Public Library of Science Medicine,
2008; 5: e95.
28 Cassels A, Hughes MA, Cole C et al. Drugs in the
news: an analysis of Canadian newspaper coverage of
new prescription drugs. Canadian Medical Association
Journal, 2003; 168: 1133–1137.
29 Smith DE, Wilson AJ, Henry DA. Monitoring the
quality of medical news reporting: early experience
with media doctor. The Medical Journal of Australia,
2005; 183: 190–193.
30 Wells J, Cheong-Leen C. NICE appraisals should be
everybody's business. British Medical Journal, 2007;
334: 936–938.
31 Culyer A, McCabe C, Briggs A et al. Searching for a
threshold – Not so. Journal of Health Services
Research and Policy, 2007; 12: 190–191.
32 Cooksey SD. A review of UK health research funding.
2006.
33 Kmietowicz Z. NICE is to root out ineffective treatments
in NHS. British Medical Journal, 2006; 333:
568a.
34 Wishart A (2009) Price of Life (BBC Television documentary).
Available at: http://www.bbc.co.uk/programmes/
b00l9dmw, accessed 17 June 2009.
35 Barrett A, Roques T, Small M et al. How much will
Herceptin really cost? British Medical Journal, 2006;
333: 1118–1120.